A detailed history of Geode Capital Management, LLC transactions in Spruce Biosciences, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 261,948 shares of SPRB stock, worth $144,071. This represents 0.0% of its overall portfolio holdings.

Number of Shares
261,948
Previous 204,002 28.4%
Holding current value
$144,071
Previous $106,000 16.04%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$0.42 - $0.59 $24,337 - $34,188
57,946 Added 28.4%
261,948 $123,000
Q2 2024

Aug 09, 2024

BUY
$0.51 - $0.85 $1,958 - $3,264
3,840 Added 1.92%
204,002 $106,000
Q1 2024

May 13, 2024

BUY
$0.7 - $5.49 $22,930 - $179,841
32,758 Added 19.57%
200,162 $158,000
Q3 2023

Nov 13, 2023

SELL
$2.04 - $2.54 $103,034 - $128,287
-50,507 Reduced 23.18%
167,404 $378,000
Q2 2023

Aug 11, 2023

BUY
$1.92 - $2.6 $301,996 - $408,954
157,290 Added 259.46%
217,911 $468,000
Q4 2022

Feb 13, 2023

SELL
$0.99 - $1.43 $132 - $191
-134 Reduced 0.22%
60,621 $66,000
Q2 2022

Aug 12, 2022

SELL
$1.28 - $2.23 $84,829 - $147,788
-66,273 Reduced 52.17%
60,755 $105,000
Q1 2022

May 13, 2022

SELL
$1.85 - $4.59 $28,565 - $70,874
-15,441 Reduced 10.84%
127,028 $255,000
Q4 2021

Feb 11, 2022

BUY
$2.33 - $5.74 $72,351 - $178,238
31,052 Added 27.87%
142,469 $635,000
Q3 2021

Nov 12, 2021

SELL
$6.01 - $11.26 $102,945 - $192,872
-17,129 Reduced 13.33%
111,417 $669,000
Q2 2021

Aug 13, 2021

BUY
$10.12 - $17.46 $192,269 - $331,722
18,999 Added 17.34%
128,546 $1.44 Million
Q1 2021

May 12, 2021

SELL
$14.8 - $25.79 $117,970 - $205,572
-7,971 Reduced 6.78%
109,547 $1.82 Million
Q4 2020

Feb 12, 2021

BUY
$15.38 - $32.42 $1.81 Million - $3.81 Million
117,518 New
117,518 $2.86 Million

Others Institutions Holding SPRB

About SPRUCE BIOSCIENCES, INC.


  • Ticker SPRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,560,200
  • Market Cap $13M
  • Description
  • Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which i...
More about SPRB
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.